Conference Presentations

PLENARY SESSIONS

  • THIRD PLENARY SESSION: UNIVERSAL HEALTH COVERAGE – THE AFFORDABLE DREAM IN ASEAN: EXPERIENCES AND LESSONS LEARNED

    Presentation

    Graham Harrison
    PhD, World Health Organization Representative to Malaysia, Brunei Darussalam and Singapore, World Health Organization (WHO), Kuala Lumpur, Malaysia
  • THIRD PLENARY SESSION: UNIVERSAL HEALTH COVERAGE – THE AFFORDABLE DREAM IN ASEAN: EXPERIENCES AND LESSONS LEARNED

    Presentation

    Syed Aljunid
    MD, PhD, Professor, Health Economics and Public Health Medicine & Head, International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia
  • THIRD PLENARY SESSION: UNIVERSAL HEALTH COVERAGE – THE AFFORDABLE DREAM IN ASEAN: EXPERIENCES AND LESSONS LEARNED

    Presentation

    Kun Zhao
    MD, PhD, MHSc, Professor & Director, Centre of Health Policy Evaluation and Technology Assessment and China National Health Development Research Centre, National Health and Family Planning Commission, Beijing, China
  • THIRD PLENARY SESSION: UNIVERSAL HEALTH COVERAGE – THE AFFORDABLE DREAM IN ASEAN: EXPERIENCES AND LESSONS LEARNED

    Presentation

    Netnapis Suchonwanich
    Former Deputy Secretary General, National Health Security Office (NHSO), Bangkok, Thailand
  • THIRD PLENARY SESSION: UNIVERSAL HEALTH COVERAGE – THE AFFORDABLE DREAM IN ASEAN: EXPERIENCES AND LESSONS LEARNED

    Presentation

    Ahmad Fuad Afdhal
    PhD, Director, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia
  • SECOND PLENARY SESSION: HARNESSING THE POWER OF BIG DATA TO MAKE BETTER HEALTH CARE DECISIONS IN THE ASIA-PACIFIC REGION

    Presentation

    Trish Williams
    PhD, Professor & Chair of Digital Health Technologies, Finders University, Adelaide, Australia
  • SECOND PLENARY SESSION: HARNESSING THE POWER OF BIG DATA TO MAKE BETTER HEALTH CARE DECISIONS IN THE ASIA-PACIFIC REGION

    Presentation

    Christopher Chute
    MD, DrPH, Bloomberg Distinguished Professor of Health Informatics, Professor of Medicine, Public Health, and Nursing, and Chief Health Research Information Officer, Johns Hopkins Medicine, Johns Hopkins University, Baltimore, USA
  • SECOND PLENARY SESSION: HARNESSING THE POWER OF BIG DATA TO MAKE BETTER HEALTH CARE DECISIONS IN THE ASIA-PACIFIC REGION

    Presentation

    Louisa Jorm
    PhD, Professor & Director, Centre for Big Data Research in Health, University of New South Wales (UNSW), Sydney, Australia
  • FIRST PLENARY SESSION: HEALTH TECHNOLOGY ASSESSMENT AND HEALTH POLICY: RECENT DEVELOPMENTS ACROSS ASIA

    Presentation

    Tae-jin Lee
    MPH, PhD, Professor, Health Economics, School of Public Health, Seoul National University and President, Korea Association of Health Economics and Policy, Seoul, South Korea
  • FIRST PLENARY SESSION: HEALTH TECHNOLOGY ASSESSMENT AND HEALTH POLICY: RECENT DEVELOPMENTS ACROSS ASIA

    Presentation

    Takashi Fukuda
    PhD, Director, Department of Health and Welfare Services, National Institute of Public Health, Saitama, Japan
  • FIRST PLENARY SESSION: HEALTH TECHNOLOGY ASSESSMENT AND HEALTH POLICY: RECENT DEVELOPMENTS ACROSS ASIA

    Presentation

    Syed Aljunid
    MD, PhD, Professor, Health Economics and Public Health Medicine & Head, International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia

ISSUE PANEL PRESENTATIONS

  • IP10 : CLINICAL TRIALS FOR REGULATORY AND REIMBURSEMENT NEEDS: DOES ONE SHOE FIT ALL?

    Presentation

    Alissa Brown
    MPH, Head of Market Access, Sanofi Australia, Macquarie Park, Australia
  • IP11 : HOW CAN RISK-SHARING AGREEMENTS IN KOREA BE IMPROVED?

    Presentation

    Hye-Lin Kim
    PhD, Assistant Professor, Sahmyook University, College of Pharmacy, Seoul, South Korea
  • IP11 : HOW CAN RISK-SHARING AGREEMENTS IN KOREA BE IMPROVED?

    Presentation

    Nam-Sun Choi
    Deputy Manager, National Health Insurance Service (NHIS), Department of Insurance Benefits, Wonju, South Korea
  • IP11 : HOW CAN RISK-SHARING AGREEMENTS IN KOREA BE IMPROVED?

    Presentation

    Kevin Haninger
    PhD, Deputy Vice President, PhRMA, International Health Policy, Washington, USA
  • IP11 : HOW CAN RISK-SHARING AGREEMENTS IN KOREA BE IMPROVED?

    Presentation

    David Grainger
    Director, Eli Lilly and Company, Global Public Policy, Sydney, Australia
  • IP12 : HOW CAN WE EMPOWER THE PATIENT VOICE IN HEALTH CARE DECISION MAKING AT THE POLICY LEVEL?

    Presentation

    Eui-Kyung Lee
    PhD, Professor, Sungkyunkwan University, Pharmaceutical Policy & Outcomes Research, School of Pharmacy, Suwon, South Korea
    Richard Vines
    Chairman, Rare Cancers Australia, Bowral, Australia
    Joerg Klug
    MA, MBA, Director, Janssen Asia Pacific, Market Access, Kowloon, Hong Kong
    Chih-Liang Yaung
    PhD, President, and former Minister of Health, TAPO (Taiwan Alliance of Patients Organizations), Republic of China, Taiwan
  • IP15 : SHOULD PRODUCTIVITY LOSSES DUE TO ILLNESS BE CONSIDERED IN HEALTH ECONOMIC EVALUATIONS?

    Presentation

    Hwee Lin Wee
    PhD, Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, -, Singapore
    Craig Brooks-Rooney
    MA, Head, Asia-Pacific, Costello Medical Singapore Pte Ltd., Singapore, Singapore
    Dominique Milea
    PharmD, PhD, Director, Health Economics & Epidemiology Asia, Lundbeck Singapore Pte. Ltd., Singapore, Singapore
  • IP2 : GROWING DEMANDS FOR HTA IN ASIA: HOW CAN PUBLIC-PRIVATE-ACADEMIC PARTNERSHIPS BE STRENGTHENED?

    Presentation

    Jörg Mahlich
    PhD, Health Economics, Janssen Pharmaceuticals KK, Tokyo, Japan
    Akio Onishi
    PhD, Professor, Graduate School of Public Policy, Tokyo, Japan
    Allen Yu-Hung Lai
    MD, MSc, MPA, PhD, Principal of Health Economics & Outcomes Research, IMS Health, Singapore, Singapore
  • IP3 : JOINT HTA: THE NEXT STEP FOR THE ASEAN ECONOMIC COMMUNITY?

    Presentation

    Gengshi Chen
    BA, MSci, MSc, Senior Analyst, Costello Medical Singapore Pte Ltd, Singapore, Singapore
  • IP4 : RISKY BUSINESS: DECISION MAKING IN HEALTH CARE WITH ECONOMIC MODELLING UNCERTAINTY

    Presentation

    Rosalie Viney
    PhD, Professor, University of Technology Sydney, Centre for Health Economics Research and Evaluation, Sydney, Australia
  • IP4 : RISKY BUSINESS: DECISION MAKING IN HEALTH CARE WITH ECONOMIC MODELLING UNCERTAINTY

    Presentation

    Paul Scuffham
    PhD, Professor of Health Economics, Griffith University, Population and Social Health Research, Gold Coast, Australia
  • IP5 : ESTIMATING COUNTRY-SPECIFIC EQ-5D-5L VALUE SETS USING A HYBRID REGRESSION MODEL: IS IT A GOOD IDEA FOR ASIA?

    Presentation

    Juan Manuel Ramos-Goñi
    MSc, Research Scientist, The EuroQol Research Foundation, Rotterdam, The Netherlands
  • IP6 : HOW DO CULTURE, VALUES, AND INSTITUTIONAL CONTEXT SHAPE THE METHODS AND USE OF ECONOMIC EVALUATION?

    Presentation

    Paul Scuffham
    PhD, Professor of Health Economics, Griffith University, Population and Social Health Research, Gold Coast, Australia
  • IP6 : HOW DO CULTURE, VALUES, AND INSTITUTIONAL CONTEXT SHAPE THE METHODS AND USE OF ECONOMIC EVALUATION?
  • IP6 : HOW DO CULTURE, VALUES, AND INSTITUTIONAL CONTEXT SHAPE THE METHODS AND USE OF ECONOMIC EVALUATION?
  • IP9 : PREDICTING FUTURE EVIDENCE: RISK-SHARING AGREEMENTS, MANAGED ENTRY SCHEMES, OR SOMETHING ELSE?

    Presentation

    Rosalie Viney
    PhD, Professor, University of Technology Sydney, Centre for Health Economics Research and Evaluation, Sydney, Australia

WORKSHOP PRESENTATIONS

  • W1 : APPLYING HEALTH TECHNOLOGY ASSESSMENT TO PRECISION MEDICINE: EVALUATING NOVEL DIAGNOSTIC TESTS

    Presentation

    W. Ken Redekop
    PhD, Associate Professor, Erasmus University Rotterdam, Institute for Medical Technology Assessment, Rotterdam, The Netherlands
  • W1 : APPLYING HEALTH TECHNOLOGY ASSESSMENT TO PRECISION MEDICINE: EVALUATING NOVEL DIAGNOSTIC TESTS
  • W12 : INTRODUCING A NOVEL CONCEPT TO OBSERVATIONAL RESEARCH IN THE ASIA-PACIFIC REGION: ENRICHED REAL-WORLD DATA STUDIES

    Presentation

    Laura Garcia Alvarez
    PhD, Engagement Manager, IMS Health, Real-World Evidence Solutions, Barcelona, Spain
    Joanne Yoong
    PhD, Assistant Professor, National University of Singapore, Singapore, Singapore
    Ong Leong Seng
    MSc, Chief Architect & Group Director, Integrated Health Information System, Ministry of Health Holdings, Architecture & Innovation, Singapore, Singapore
    Joshua Hiller
    MBA, Senior Principal, IMS Health, London, UK
  • W2 : EVOLVING METHODS FOR STAGING PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN MATURE AND EMERGING MARKETS

    Presentation

    Linda Liong
    MSc, Project Director, Late Stage Operations, APAC, inVentiv Health, Singapore, Singapore
  • W3 : AN INTRODUCTION TO THE CASEMIX DATABASE IN MALAYSIA, INDONESIA, AND PHILIPPINES

    Presentation

    Soraya Azmi
    MD, MPH, Managing Director, Azmi Burhani Consulting, Petaling Jaya, Malaysia
    Syed Mohamed Aljunid
    MD, MSc, PhD, President, ISPOR Malaysia Chapter and Professor of Health Economics, & Head of the International Centre for Casemix and Clinical Coding, National University of Malaysia, Faculty of Medicine, Kuala Lumpur, Malaysia
    Adrian Goh
    MEc, Health Economist, Azmi Burhani Consulting, Petaling Jaya, Malaysia
    Amrizal Muhd Nur
    MD, MSc, PhD, Senior Research Fellow, Universiti Kebangsaan Malaysia, Cheras, Malaysia
  • W4 : COMBINING TWO TYPES OF VALUATION DATA TO ESTIMATE HEALTH STATE UTILITIES: THE HYBRID REGRESSION MODEL
  • W6 : ADAPTING PHARMACOECONOMIC DATA OF ANALYSES FROM OVERSEAS FOR USE IN DECISIONS IN MIDDLE INCOME COUNTRIES
  • W6 : ADAPTING PHARMACOECONOMIC DATA OF ANALYSES FROM OVERSEAS FOR USE IN DECISIONS IN MIDDLE INCOME COUNTRIES

    Presentation

    Jasmine Pwu
    PhD, Senior Investigator, National Taiwan University, Health Data Research Centre, Taipei, Taiwan
  • W6 : ADAPTING PHARMACOECONOMIC DATA OF ANALYSES FROM OVERSEAS FOR USE IN DECISIONS IN MIDDLE INCOME COUNTRIES
  • W6 : ADAPTING PHARMACOECONOMIC DATA OF ANALYSES FROM OVERSEAS FOR USE IN DECISIONS IN MIDDLE INCOME COUNTRIES
  • W7 : SHARING REAL-WORLD DATA EXPERIENCES OF USING TAIWAN’S NATIONAL HEALTH INSURANCE RESEARCH DATABASE

    Presentation

    Chung-Hsuen Wu
    PhD, Assistant Professor, Taipei Medical University, Department of Clinical Pharmacy, Taipei City, Taiwan
  • W7 : SHARING REAL-WORLD DATA EXPERIENCES OF USING TAIWAN’S NATIONAL HEALTH INSURANCE RESEARCH DATABASE

    Presentation

    Ming-Hui Tai
    MS, MHPA, PhD, Lead Outcomes Research Analyst, Pharmerit International, Bethesda, USA
  • W8 : APPLIED EARLY ECONOMIC MODELLING FOR COMBINATION THERAPIES IN ONCOLOGY: NOVEL VALUE-BASED PRICING APPROACH

    Presentation

    Meghan Gallagher
    Director, Sanofi, Global Health Economics and Outcomes Research, Oncology, Cambridge, USA
    Kateryna Onishchenko
    PhD, Health Economist, CBPartners, London, UK

ISPOR FORUMS

  • F1 : HEALTH TECHNOLOGY ASSESSMENTS IN UNIVERSAL HEALTH COVERAGE
  • F1 : HEALTH TECHNOLOGY ASSESSMENTS IN UNIVERSAL HEALTH COVERAGE
  • F1 : HEALTH TECHNOLOGY ASSESSMENTS IN UNIVERSAL HEALTH COVERAGE
  • F2 : INTEGRATING EVIDENCE-BASED AND COST-EFFECTIVE COMPLEMENTARY AND ALTERNATIVE MEDICINE INTO THE HEALTH CARE SYSTEMS IN ASIA

    Presentation

    Wendy Wong
    PhD, Assistant Professor, The Chinese University of Hong Kong, Hong Kong Institute of Integrative Medicine, Assistant Professor, School of Chinese Medicine and Deputy Chief Chinese Medicine Practitioner, Integrative Medical Centre, Faculty of Medicine, Hong Kong, China
  • F2 : INTEGRATING EVIDENCE-BASED AND COST-EFFECTIVE COMPLEMENTARY AND ALTERNATIVE MEDICINE INTO THE HEALTH CARE SYSTEMS IN ASIA

    Presentation

    Ming Hu
    PhD, Professor & Director, West China School of Pharmacy, Sichuan University, Pharmaceutical Policy & Pharmaceonomics Research Center, Chengdu, China
  • F2 : INTEGRATING EVIDENCE-BASED AND COST-EFFECTIVE COMPLEMENTARY AND ALTERNATIVE MEDICINE INTO THE HEALTH CARE SYSTEMS IN ASIA

    Presentation

    Hwee Ling Koh
    PhD, Associate Professor, National University of Singapore, Department of Pharmacy, Singapore, Singapore
  • F2 : INTEGRATING EVIDENCE-BASED AND COST-EFFECTIVE COMPLEMENTARY AND ALTERNATIVE MEDICINE INTO THE HEALTH CARE SYSTEMS IN ASIA

    Presentation

    Namkwen Kim
    KMD, MPH, PhD, Professor, Monitoring Center for Korean Medicine and Western Collaboration, Pusan National University Korean Medicine, Pusan National University School of Korean Medicine and Director, Yangsan, South Korea
  • F3 : BIG DATA IN ASIA-PACIFIC – A VALUABLE RESOURCE FOR BETTER HEALTH CARE DECISIONS: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN, SINGAPORE, SOUTH KOREA, AND TAIWAN
  • F3 : BIG DATA IN ASIA-PACIFIC – A VALUABLE RESOURCE FOR BETTER HEALTH CARE DECISIONS: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN, SINGAPORE, SOUTH KOREA, AND TAIWAN

    Presentation

    Seungjin Bae
    PhD, Associate Professor, Ewha Womans University, Pharmacoeconomics and Outcomes Research, College of Pharmacy, Seoul, South Korea
  • F3 : BIG DATA IN ASIA-PACIFIC – A VALUABLE RESOURCE FOR BETTER HEALTH CARE DECISIONS: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN, SINGAPORE, SOUTH KOREA, AND TAIWAN

    Presentation

    Libby Roughead
    PhD, Research Professor, Division of Health Sciences, School of Pharmacy and Medical Sciences, and Director, the Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, the Quality Use of Medicines and Pharmacy Research Centre, Adelaide, Australia
  • F3 : BIG DATA IN ASIA-PACIFIC – A VALUABLE RESOURCE FOR BETTER HEALTH CARE DECISIONS: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN, SINGAPORE, SOUTH KOREA, AND TAIWAN
  • F4 : VALUE IN HEALTH REGIONAL ISSUES: GUIDANCE ON WRITING GOOD SCIENTIFIC MANUSCRIPTS FOR PUBLICATION

    Presentation

    Jianfei (Jeff) Guo
    PhD, RPh, Professor of Pharmacoeconomics & Pharmacoepidemiology, University of Cincinnati, Division of Pharmacy Practice & Administrative Sciences, College of Pharmacy, Cincinnati, USA
  • F4 : VALUE IN HEALTH REGIONAL ISSUES: GUIDANCE ON WRITING GOOD SCIENTIFIC MANUSCRIPTS FOR PUBLICATION

    Presentation

    Shu Chuen Li
    PhD, Professor, The University of Newcastle, School of Biomedical Sciences and Pharmacy, Newcastle, Australia
  • F4 : VALUE IN HEALTH REGIONAL ISSUES: GUIDANCE ON WRITING GOOD SCIENTIFIC MANUSCRIPTS FOR PUBLICATION

    Presentation

    Nathorn Chaiyakunapruk
    PharmD, PhD, Co-Editor, ViHRI (Asia) and Professor of Health Economics, Monash University Malaysia, School of Pharmacy, Kuala Lumpur, Malaysia
  • F4 : VALUE IN HEALTH REGIONAL ISSUES: GUIDANCE ON WRITING GOOD SCIENTIFIC MANUSCRIPTS FOR PUBLICATION

    Presentation

    Kenneth K. C. Lee
    MPhil, PhD, Co-Editor, ViHRI (Asia) and Professor of Pharmacy & Head of School of Pharmacy, Monash University Malaysia, Kuala Lumpur, Malaysia
  • F4 : VALUE IN HEALTH REGIONAL ISSUES: GUIDANCE ON WRITING GOOD SCIENTIFIC MANUSCRIPTS FOR PUBLICATION

    Presentation

    Bong-Min Yang
    PhD, Professor of Economics, Seoul National University, School of Public Health, Seoul, South Korea
  • F5 : PHARMACOECONOMIC GUIDELINES IN CHINA, INDIA, INDONESIA, MALAYSIA AND THAILAND

    Presentation

    Sitaporn Youngkong
    PhD, Lecturer, Mahidol University, Department of Pharmacy, Faculty of Pharmacy, Bangkok, Thailand
  • F5 : PHARMACOECONOMIC GUIDELINES IN CHINA, INDIA, INDONESIA, MALAYSIA AND THAILAND
  • F5 : PHARMACOECONOMIC GUIDELINES IN CHINA, INDIA, INDONESIA, MALAYSIA AND THAILAND

    Presentation

    Amad Fuad Afdhal
    PhD, Director, Center for Socio-Economic Studies in Pharmacy, Cirendeu, Indonesia
  • F5 : PHARMACOECONOMIC GUIDELINES IN CHINA, INDIA, INDONESIA, MALAYSIA AND THAILAND

    Presentation

    Mahendra Kumar Rai
    MPharm, Group Leader & SME, HEOR & Real-World Evidence, Tata Consultancy Services, Market Access & HEOR, Mumbai, India